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Abstract
This article poses the question of whether biobanking practices and standards are
giving rise to the construction of populations from which various biobanking
initiatives increasingly draw on for legitimacy? We argue that although recent
biobanking policies encourage various forms of engagement with publics to ensure
legitimacy, different biobanks conceptualize their engagement strategies very
differently. We suggest that biobanks undertake a broad range of different strategies
with regard to engagement. We argue that these different approaches to
engagement strategies are contributing to the construction of populations, whereby
specific nationalities, communities, societies, patient groups and political systems
become imbued or bio-objectified with particular characteristics, such as compliant,
distant, positive, commercialized or authoritarian. This bio-objectification process is
problematic in relation to policy aspirations ascribed to biobanking engagement
since it gives rise to reified notions of different populations.
Keywords: Biobanking; Bio-objects; Engagement; Governance; Populations;
Standards
Introduction
The success of any research project has a direct relation with the trust of
participants that will voluntarily accept to provide samples and, usually, private
information about their health and living habits. To secure the trust of all partners,
including participants and the larger community to which they belong, public
information, consultation and public participation seems one of the most important
factors influencing success. (European Union 2010, 131)
Recently, Kowal (2013) has noted that no research using samples and information is
safe, unless researchers establish and maintain relationships with the communities
from which samples come from. This normative observation may provide important
insight into the development and maintenance of sustainable global biobanking initia-
tives and their relationship with the local/regional/national/global context in which
they are embedded. Public participation and involvement is by no means a new topic
in relation to techno-political legitimacy. Arnstein’s (1969) ladder of participation is a
classic example of the ways in which involvement has been made a political issue in re-
lation to planning and development where increased levels of involvement are seen to
be desirable.
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This article poses the very simple question of whether biobanking practices and stan-
dards related to the ethical, legal and social aspects of biobanking are, in fact, giving
rise to, and construction of populations from which biobanking initiatives (national, re-
gional, local, disease-based, patient group based etc.), such as deCode, 23andMe, CARTa-
GENE and UK Biobank, draw on for legitimacy? Recent biobanking policies encourage
various forms of engagement with populations to ensure legitimacy (European Union
2010), yet different countries and biobanks conceptualize their engagement strategies very
differently. Snell et al. (Snell, Karoliina, Jose A. Cañada, and Aaro Tupasela: Strategies and
practices of biobank engagement, submitted.) have develop a typology of public engage-
ment from the viewpoint of the biobanks where they suggest that although there are a
number of policy guidelines for engagement, biobanks in fact, undertake a broad range of
different strategies with regard to engagement. We argue in this paper that these different
approaches to engagement strategies are also giving rise to the construction of popula-
tions, whereby specific nationalities, populations, patient groups and political systems be-
come imbued with particular characteristics, such as deliberative, consensus seeking,
commercialized or authoritarian (cf. Jones and Salter 2003). We see this as a type of co-
construction of identity, whereby the population from which the biobank draws from,
helps to define and characterize the biobank, but also that the identification, collection
and distribution of samples and data also give rise to the construction of a population at
the same time (cf. Appiah 2005). This co–construction can also be understood as a form
of bio-objectification whereby the governance of biobanks give rise to popular conceptual-
izations of the population they draw their material from (Vermeulen et al. 2012). The pro-
cesses of bio-objectification of populations, however, are not uniform, but rather take on
different characteristics and paths depending on the types of engagement practices that
various biobanks undertake in their operations. In addition, we see the process of bio-
objectification as an iterative process between historical, political and scientific activities
where these different spheres interact with each other in different configurations and
ways. The process of bio-objectification gives rise to forms of legitimation through which
local, regional, national and supra—national actors seek to leverage and utilize samples in
a more efficient way. We see this process contributing to the politicization of populations
in Europe and elsewhere, whereby groups of people are ascribed particular types of char-
acteristics (not only in a medical sense, but also in a public opinion and political action
meaning as well) in relation to engagement and biobank perspectives, as opposed to un-
derstanding public opinion and perceptions as being fluid and changing over time, requir-
ing regular interaction and dialogue (Tupasela Aaro: Branding populations in medical
research – placing genes on the global genetic atlas, submitted).
These construction processes draw on a broad range of influences and activities related
to the ethical, legal and social aspects of managing biobanks. The influences may be
drawn from historical, cultural, political, scientific spheres or any other source, which can
be leveraged to construct populations, which are seen to be more compliant and support-
ive of biobanking in general. In a general sense, the process can be seen as an attempt at
stabilizing the populations from which biobanks draw their material from (cf. Douglas
2012). One important example of engagement has often been seen the production of
population surveys, ethnographic studies of populations (Kowal 2013; Pálsson 2007), case
studies of specific biobanks (Haimes and Whong-Barr 2003), focus group studies (Snell
et al. 2012), ELSI studies on biobanking (Kaye et al. 2012; Hardcastle 2007) or other
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studies, which have sought to explore the underpinning of human tissue procurement
and use (Rabinow 1999). These perspectives, although providing important insights into
the local and regional perspectives of people regarding biobanking also have an unin-
tended consequence of standardizing conceptions of attitudes, which can be used in many
cases to draw on for legitimacy. We see this as contributing to the bio-objectification of
populations, which can also be understood in some respects as a form of population
branding (Tupasela 2012). These studies have also contributed to constructions of racial-
ized notions of populations (Reardon and TallBear 2012; TallBear 2003). According to Igo
(2007), this contributes to the development of a notion of self, giving rise to certain types
of vocabulary that are affiliated with particular populations or groups of people. Some
have also suggested that this can also give rise to false notions of consensus regarding spe-
cific issues, such as informed consent (Master et al. 2012). Besides biobanks drawing on
reified notions of common history and national identity (Schwartz-Marin and Silva-
Zolezzi 2010), they can also be seen as contributing to normative assumptions on the
opinions of the people who participate in them, or more specifically the people who are
surveyed and interviewed for their opinions on them.
One of the most common motifs of vocabulary draws from that of participatory en-
gagement. Participatory models of engagement rely to a certain extent on an under-
standing that increased participation also increases the flow of information in both
directions, as opposed to being top-down in nature. From a governance perspective,
such a position may hold important possibilities for interaction in relation to biobank-
ing. Some have argued that increased involvement makes visible the ‘patient work’
(Corbin and Strauss 1985) and ‘clinical labor’ (Cooper and Waldby 2014) that sample
donors provide in order for collections to become possible and operable, as well as al-
lows for increased responsiveness to the interests and concerns of those who have
participated. Community engagement is seen as a central aspect of any biobanking gov-
ernance scheme (Halderman et al. 2014; O’Doherty et al. 2011; Shalowitz et al. 2009).
The basic theoretical assumptions underlying engagement with the research population
stem from an understanding and belief that engaging with the research population will
bring with it improved understanding of the context in which research takes place, as
well as improved results in the outcomes of the research and public health (NIH 2011).
Studies of patient activism are another example, which have indicated that patient
organizations are increasingly involved in the organization of research and sample acquisi-
tion surrounding specific diseases and rare conditions (Rabeharisoa and Callon 2002).
These novel knowledge-making coalitions between patients and research organizations, as
well as companies, highlight the ways in which citizen and patient participation is in some
cases becoming more prevalent and inclusive in biomedical research (Epstein 2007), but
also the ways in which patient organizations are increasingly becoming a political
apparatus for mobilization of resources. This mobilization and the legitimacy that it
carries are in part based on standardized notions of patient organizations and their
members as actively interested in such forms of participation. Callon and Rabeharisoa
(2008) note that such groups play an increasingly important role in the development of
technoscience, politics, and economic life. Yet in many cases patient organizations are not
as active in engaging with biomedical research, but rather far more involved in providing
peer support to their members. If indeed biobanking and the supporting infrastructure
surrounding the systems through which information on patients will be collected, stored
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and studied, the concern with the forms and styles of engagement and governance be-
come all the more significant.
We argue, however, that the certain specificities within national, regional and institu-
tional contexts are giving rise to the construction and bio-objectification of populations
and publics in relation to biobanking, whereby engagement is understood in a very diverse
manner that rises in connection with the individual context of a given biobank. The way
public engagement is constructed and understood by different biobanks in their individual
contexts is from where arguments that validate their legitimacy draw from. In our analysis
we are drawing on the notion of populations as a collection of individuals which are stud-
ied and acted upon scientifically and medically. The notion of public, however, is used
more to connote a political body of people which is engaged with. These two conceptions,
however, are not separable in that in biobanking the populations which are studied and
medically acted upon are also necessarily publics which have political significance. What
is of interest, however, is the ways in which the two categories become collapsed and posi-
tioned differently depending on each biobanks engagement strategy.
The empirical material analyzed in this research is based on a two-year project, which
examined and explored the forms and styles of engagement that various biobanks
undertook in six countries: USA, Canada, UK, Spain, Finland and Iceland. The scope of
our research focused on engagement strategies of biobanks in these different countries.
In our research we conducted 16 semi-structured interviews with relevant personnel
from different biobanks, as well as biobank networks in the six countries. We also con-
ducted six interviews with policy makers and regulators to develop a broader picture of
the nature of engagement undertaken by various biobanks in the different countries.
Policy makers were defined as people who worked solely in government ministries or
regulatory bodies, since in many cases it became apparent that biobank managers also
had a significant impact on the ways in which national biobank policies were devel-
oped. Furthermore, in many countries the regulatory process of rewriting legislation
and policy often involves an interative process between various stakeholders, which
blurs the categorical differentiation between various actors. We supplemented the in-
terviews with international (European Commission 2012; OECD 2009) and national
policy documents from the various countries (National Cancer Institute 2011), as well
as different types of documents that we could find that had been published by or about
the various biobanks, which we were studying (Auria Biobank 2014). These documents
included different types of white papers and preparatory documents, as well as national
legislations and recommendations (cf. Biobank Act 2012). In selecting the countries
and biobanks that we would study, we sought to cover a broad range of different types
of biobanks, as well as regions, taking into account both the size of the country, type of
healthcare systems they had, as well as the legal structures which are in place. For this
article, we selected Canada, Spain and Finland since they are very different in terms of
their approaches to biobanking and historically diverse. We draw examples from these
countries in order to show the ways in which populations are becoming increasingly
constructed as a way through which legitimacy is drawn from.
In the following, we will briefly discuss the issue of constructed population and the
normative problems it has in relation to the legitimation of biobanking activities. We
will then draw on our empirical material to provide some concrete examples of the
ways in which this has become manifested in different contexts.
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Constructing biobank populations
A number of recent studies have suggested that populations have become associated
with varying conceptions of race, ancestry and ethnicity, which derive legitimacy from
genomic studies (Whitmarsh and Jones 2010; see also Tupasela 2015). Numerous gen-
omic studies seek to reveal the genomic characteristic of specific populations, thus
claiming to provide some form of objective measure and delineation between different
groups of people (cf. Reich et al. 2009). Similarly, Igo (2007) has argued that different
types of population surveys, polls and gallops and other studies help construct the ways
in which the population and their perceptions and opinions are projected, giving rise to
reified notions of national self. Within the field of biobanking there is a large corpus of
studies examining public opinions regarding biobanks and their operations (Lemke et
al. 2010; Tupasela et al. 2015; Kettis-Lindblad 2007; Hoeyer 2008; Stegmayr and
Asplund 2002). These studies contribute to a standardized understanding of popula-
tions from which a number of biobanks and policies draw legitimacy from in the long-
term. The collection, use and distribution of human tissue samples, which include
blood and diagnostic tissue samples, from which DNA can be extracted and analyzed,
has become a major political preoccupation, not only in national contexts, but also at
the transnational level (Gottweis 1998) in that increasingly such sample collections are
not just expected to produce commercial value (Caulfield 2012), but also seen to repre-
sent a form of national capital from which research can draw from both in a scientific
sense, but increasingly in a symbolic manner. In this symbolic relation, populations are
increasingly seen to be the target of research (providing new treatments and medi-
cines), but also draw on the population for their legitimacy. As such, populations have
increasingly become the target of processes of bio-objectification, whereby specific pop-
ulations or groups of people are ascribed various characteristics from which biobanks
and policy makers draw on for legitimacy.
In a number of countries, issues surrounding the relationship between biobanks and
the research population have maintained a central role in policy-making and politics as
well (Epstein 2007). In the US, for example, The Centers for Disease Control and Pre-
vention (CDC) has placed a great deal of emphasis in developing strategies for commu-
nity engagement in an attempt to improve public health, as well as improve the quality
and applicability of population research (Haldeman et al. 2014). Although the use of
human tissue in biomedical research is not in itself new (Strong 2000), some have argued
that recent biomedical research practices using tissue sample collections constitute a new
object of study within biomedical research (von Versen 2000). Internationally, the forma-
tion of networks of biobanks and protocols for standards indicates a professionalization of
the field itself whereby the population and people from which samples are gathered are
becoming increasingly a political preoccupation. Therefore, in order to maintain the col-
lection and research activities surrounding biobanking efficient and validated, biobankers
and policy makers need to become increasingly attuned to what the public thinks. At the
same time, however, this process can give rise to what Lippmann (1993) has termed the
phantom public (see also Gottweis et al. 2011). In our research, however, we have noticed
that many biobanking initiatives follow somewhat different definitions and practices of
public engagement, and that in many cases, the public is only one target of engagement
among many others. This variation can also be seen as a way of constructing the public as
either an active or passive partner in the research process.
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A number of national biobanking initiatives have sought to draw on a discourse of par-
ticipation and involvement in an attempt to garner broader social legitimacy (Corrigan
and Tutton 2006). The public shaping of science has indeed gained an important role in
current social studies of the public’s role in a number of research fields, including environ-
mental movements and patient advocacy groups (Kerr et al. 1998; see also Fuller 1999),
yet it can be argued that science is also continually constructing the public as well. Along
these lines, Barry (2001), 2 has suggested that the technological society brings forth a “pol-
itical preoccupation with the problems technology poses, with the potential benefits it
promises, and with the models of social and political order it seems to make available.” In
this context, it is unsurprising that the question of engagement practices in biobanking is
of political and practical interest.
The construction of populations in relation to biobanking has been seen in a number
of international commercial biobanking ventures which have been developing new ways
in which to collect and analyze genetic information and connect it with self-reported
health information, namely through genetic self-testing. These commercial efforts can
be seen as “joint social efforts” in which populations are constructed in new ways.
Companies such as 23andMe, deCODEme, as well as sites like PatientsLikeMe, have
sought to develop models that utilize technologies and combine them with various
forms of social media through which to engage customers in their services. This form
of biobanking represents new ways of constructing populations as engaged and net-
worked. Some authors have also noted how biobanking ventures have sought new ways
in which benefits can be distributed between a broader range of actors in an effort to
foster trust and legitimacy (Simm, 2005). The innovations that these business models
represent seek to develop new forms of engagement with research subjects, but at the
same time are based on notions of the public as active in specific social ways and thus
develop forms of social interaction with customers that may someday be commercially
sustainable.
For public health initiatives, participation in studies is a crucial element for success
and validity. During the past decades, the levels of recruitment of participants to sur-
veys, for example, have declined dramatically (Helakorpi et al. 2011; Raisamo et al.
2011, 17), posing a serious challenge regarding the future possibilities to gather relevant
scientific and medical data for large studies. From a political and sustainability perspec-
tive this can also be seen as a major challenge to legitimacy. The dramatic decline in
participation levels raises important policy concerns regarding recruitment and its rela-
tion to scientific output and innovations.
It is in this context that biobanks have perhaps drawn on previous experiences of re-
sistance and opposition movements. The organization Mannvernd, for example, was
created specifically to oppose the deCode Genetics in Iceland being given monopoly
rights to use Icelandic information and as a result about 10 % of Icelanders chose to
opt-out of the database. In Tonga, an Australian biotech firm Autogen ran into major
opposition as a result of failures to account for cultural differences and customs in
Tonga. Despite having signed a contract with Tonga’s health ministry to perform re-
search on the population, local opposition and churches in the Pacific united to oppose
such ventures without extensive prior public consultation. The opposition was primar-
ily based on the fact that the informed consent procedures did not account for the ex-
tended family system that plays a major role in Tongan society. Other oppositions
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included giving patent monopolies to corporations on God-created life forms (Burton
2002, 443). These examples show the ways in which biobanking activities have given
rise to the politicization of populations. Despite being examples of opposition and re-
sistance, we believe that they also highlight the way in which biobanking initiatives have
sought to ameliorate such oppositions by conducting exercises in public engagement.
Yet, in relation to long-term sustainability efforts, we have observed that these engage-
ment practices are seen more as a necessary process, which much be gone through in
order to maintain legitimacy.
The lessons that have emerged from such contentious events have indicated that the
collection and use of biomedical tissue samples and related information should not be
taken lightly. Instead, there appears to be a movement towards a more systematic and
professionalized field of experts, with specific formation on biobanking, who run and
operate biobanking activities, and take engagement with various stakeholders as an im-
portant function of their overall operations. Yet the ways in which engagement is oper-
ationalized and the influence this has on the way research populations are constructed
varies greatly from one context to another. In the following we will explore three exam-
ples drawn from our empirical material where we think that biobanking practices are
giving rise to the construction of different types of populations. We see this process to
be highly political in nature and suggest that the practical day-to-day policy work and
practices of governing and running biobanks are giving rise to this politicization of
populations.
Canadian provincial biobanks
Canadian discussions on ethical, legal and social issues of biobanking and aspects of public
engagement have been relatively visible internationally. Prominent Canadian experts of
these issues have been involved in setting up the governance of biobanks and have partici-
pated in international ethical discussions (Caufield and Knoppers 2010). Numerous surveys
about public opinions in different provinces have been produced (Caulfield et al. 2012,
Pullman et al. 2012) and biobanking efforts such as CARTaGENE in Quebec or BC Gener-
ations Project and BC Bio Library in British Columbia have been active in consulting stake-
holders prior to the launching of the biobank and consequently constructing a certain type
of population (Godard et al. 2004, O’Doherty and Burgess 2009, O’Doherty et al. 2012). In
addition, Canadian medical genetics has sought to connect various populations and their
historical roots to the possible future medical treatment regimes of the predominantly fran-
cofone population by suggesting that these populations have unique actionable genetic
characteristics that can be used in diagnostics and treatment (Laberge et al. 2005).
Our interviews, as well as literature on public opinions in Canada, indicate that
public attitudes in the different provinces have been mainly very positive towards bio-
banking and biomedical research. Canadians regard biobanks as public goods that con-
tribute primarily for public benefit. This view has been manifested also in the literature
where biobanks are framed as big public and local projects: “large state projects take
on a civic character. They are not simply research on humans, but represent significant
public investment and interests.” (O’Doherty et al. 2011).
On one hand this picture of the content and willing public has been formed through
opinion surveys, on the other is based on more active engagement and interaction with the
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public. For example, in the beginning stages of CARTaGENE, a partnership model for the
public engagement was promoted (Godard et al. 2004). In the BC generations project a
considerable effort has been made to engage the public in the decision making of the bio-
bank (O’Doherty and Burgess 2009). Despite of aims, all biobanks have not however been
able to create or sustain a partnership model where the public actively engages with bio-
banks. Biobankers we interviewed acknowledged that they could do more with public
engagement.
“There was some sort of public consultation before the beginning of the project. But
they had targeted selected groups of stakeholders and experts to sort of define the roles
of the project and the main objectives of the project. It wasn’t a public, it wasn’t open to
the public per se.... I have to say we haven’t been really strong at working with the
community.” (Interview with epidemiology director of a biobank, Canada, 2014)
The active promotion of the engagement of the public has, however, constructed a type
of population that is positive, willing to contribute to common good but is not too
interested, or to put it in another way, has enough trust towards the institutions involved
in biobanking. This has served the purposes of the biobanks well as they have been
launched and are functioning without any major resistance or public controversies.
People do not have any major concerns” (Interview with biobank manager,
Canada, 2014)"
A critique singled out by our interviewees was that people are interested in getting
information about their research results. Research on participants from CARTaGENE also
showed that people would be motivated if they received research results (Godard et al.
2007). The big provincial biobanks such as CARTaGENE or the Tomorrow Project do not,
however, by default return individual research results – only measurements done at the
time of sample taking or recruitment.
Another aspect in the construction of Canadian biobank populations is that they are
framed as being very nationalistic as regards to the provinces. The biobanks themselves
promote the idea of provincial nationalism by stressing how the research can help the local
populations (Laberge et al. 2005). CARTaGENE advertises its goals on the web pages as
“for the health of Quebecers and future generations”. The Tomorrow project from Alberta
talks about how the project can help in treating cancer: “cancer affects everyone in some
way. Here in Alberta, 1 in 2 Albertans will be diagnosed with cancer in their lifetime, and 1
in 4 will die from it.” Biobankers we interviewed recognized that people were motivated by
the possibility to contribute to the public good or health in their own province. Similar
tendencies can also be seen in relation to Finnish biobanks (Tupasela and Snell 2012).
During recent years there have been major transformations occurring in the biobank
sector, both internationally as well as inside Canada. First of all, the locality of biobanks is
becoming increasingly blurred as the biobanks are more actively and openly becoming
parts of networks, such as the Canadian Partnership for Tomorrow Project (CPTP) which
is a multimillion dollar research platform with currently almost 300 000 participants from
different parts of Canada. The core of the platform is comprised of five regional biobanks:
CARTaGENE (Quebec), Ontario Health Study (Ontario), Tomorrow Project (Alberta),
Atlantic Path (Atlantic provinces), and BG Generations Project (British Columbia).
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Biobankers we interviewed expressed that this has caused discontent in some participants
as the focus of the project has shifted from provincial to federal. A notable part of those re-
cruited earlier did not want to re-enroll in the biobank as it was becoming part of a federal
network.
“They joined in an Albertan project. Alberta likes to be independent from the federal
government. It is a challenge for being a part of a federal project.” (Interview with
biobank manager, Canada, 2014)
A second change is related to the increasing pressure to return individual research
results. It is not only a motivational factor coming from the public but also a vivid topic
of scientific, ethical and legal discussion internationally and in Canada. This has created
pressure to change the perception of the ideal populations from a content, nationalistic
population that is motivated by public good to one that is more interested in the indi-
vidual research results and has to be more internationally open-minded. From a policy
perspective this has become a challenge since there is a lack of international normative
standards on the return of individual research results (IRR) and incidental findings (IF)
(Zawati and Knoppers 2012).
In summary, the construction of the population by Canadian biobanks has been
characterized by an initial depiction of the public as content and participative. This,
with the evolvement of the several national and regional projects, has developed into a
different scenario. Firstly, donors and patients have grown to be less content discontent
with regional projects as they became part of national federalized biobank network
associations. Secondly, the lack of direct and personalized results has also affected their
attitude towards the projects. These changes have result into a lowering of the willing-
ness in the participants to re-enroll for future biobank projects.
The public as a secondary engagement target: constructing populations by default in the
Spanish context
In our interviews with Spanish biobankers, engaging the general population, patients
and donors often seemed to be an activity relegated to the background by other prior-
ities. While most biobank literature pays attention to the engagement with the public
and, which we also sought to explore in our interviews, the conversation always turned
towards other actors that also need to be engaged, but who are usually not considered
in terms of engagement (Cañada, Jose A., Aaro Tupasela, and Karoliina Snell: Beyond
and within public engagement–Communities biobanks engage with, submitted). Some
of these communities were other biobanks, industry, doctors, clinicians, researchers,
funding organizations and public administration. Therefore, the general population is
constructed almost by default in the Spanish context in relation to other more promin-
ent actors. However, the focus on other engaged communities, has had positive conse-
quences as the “Spanish design” of biobank networking, as pointed out by one of our
interviewees, has often served as an example for the international community (see also
Romeo Casabona et al. 2011).
Regarding public engagement, in our interviews with Spanish biobankers, it became
apparent that in some of the regions, framing biobanks in terms of population-based
collections seemed to be a sensitive issue:
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It is a very sensitive topic, you always need to be very careful, nowadays it is less
complicated, but there is always that dogma about mixing science and politics. We
set it out very clearly as a research project, which requires the collection of a series
of very concrete samples […], we try to unlink science and politics. (Interview with
biobank manager, Spain, 2014)
In other countries, such as the cases of UK Biobank in the United Kingdom,
deCODE in Iceland, or CARTaGENE in Quebec, claiming to aim at representing a
region’s or nation’s genome may appear much more legitimate, and even useful for the
sake of increasing funding and donors. This situation seems to be different in cases of
countries with a complicated nationalistic past, as it is, for example, the case of
Germany (Schneider 2008), despite the fact that a biobank framed as population-based
gives increased scientific appeal and power to sample collections. The history of
nationalistic disputes that characterizes the political atmosphere in Spain may have
not allowed for the construction of populations as one unitary whole. Biobanks need
to, therefore, define themselves and their competitive advantage through other means
and interactions that do not include populations: economic interactions with industry,
associative interactions with other biobanks or researchers become imperative in
defining the biobank’ identity. At the same time, in Spain, the nationalistic conflicts
are often dealt with caution in research so as to not politicize such research.
On the other hand, from a utilitarian perspective, to engage directly with patients
and donors is not the optimal course of action in the Spanish biobanking scene. Re-
cruitment is usually done through third parties, such as clinicians. This allows biobanks
to distance themselves from possible privacy controversies. As one biobank manager
noted in one of our interviews:
Most of the researchers are against this law [the Biomedical Research Law].
Because they think that it hinders research, because before, researchers would
manage the samples themselves and this law is, especially, protecting the rights of
donors and patients. And there have been quite many protests from the research
community. […]. [The Biomedical Research Law] does not benefit [the donor], it
protects [her or him]. It does not benefit [her or him] because the donor does not
perceive it, but it protects, because it is a law that establishes a very extensive
informed consent document. I believe that in some way they cover their backs in
front of a still uncertain future regarding mass sequencing and genic therapy and
such (Interview with biobank manager, Spain, 2014)
In this interview excerpt we can see how the constructed population is different de-
pending on who is constructing it, biobankers or policymakers. Biobanks seem to see
donors as something they need to reach; something they depend on, but that brings
hindrance to research. In terms of policymaking they are constructed as something to
protect, but also as a threat. If the law does not cover all sorts of uncertain facts related
to biotechnology and research, it may backfire in the judicial system. The lack of public
controversies in Spain, if we compare with the cases of UK or Iceland where there has
been lively debates concerning large national biobanking initiatives, could be one of the
reasons of why biobanks do not see interacting directly with the public as a priority.
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In our interviews, privacy concerns did not appear as a real possibility and, in some
cases, samples were not anonymized, but just coded, as data was not considered to be
sensitive. This has probably allowed biobanks to focus on other types of engagement
rather than public. It is easy to see in our interviews certain precaution with regard to
their interaction with patients. This influences heavily the way biobanks engage with
patients and donors, often preferring to leave the direct contact to other actors, such as
clinicians, or to rely on press. As it was noted in one interview:
We have not done that sort of relationship exercise [with society]. What we actually
do, every time we can, is to appear in the media to divulgate the idea of the biobank.
(Interview with biobank manager, Spain, 2014)
But even this indirect engagement is something that is usually placed in the to-do list
of the biobanks. The importance of patients and donors is recognized in discourse as
they are biobanks’ “first bulwark”, but public engagement is not so easily achieved. All
of our interviewees saw the objective of engaging with society as a pending objective
describing one of them their relationship with society as “little or null” and being “one
of their pending objectives” as “most of people do not know what biobanks are”.
Nevertheless, the secondary role played by patients is not necessarily an essential fea-
ture of the Spanish biobanking scene, but a consequence of complicated socioeconomic
entanglements resulting from recent Spanish history. Besides nationalistic disputes, the
economic crisis has provoked the current moment to not be the best for research in
Spain, as noted by one of our interviewees. This forces biobanks to engage with other
actors such as other biobanks, the international community or the industry. In one
interview, it was noted that
There’s a clear survival challenge, to depend on public funding with the current
economic situation in Spain is very complicated and one of our main concerns is to
penetrate the reproductive industrial fabric, so to be able to give steps so this
platform, in case the official funding would cease, could go on being viable and
sustainable over time (Interview with biobank network coordinator, Spain, 2014)
The types of population constructed in our interviews with Spanish biobankers are
the result of two processes. On the one hand, the sensitiveness of creating population-
based biobanks and, on the other hand, the necessity of prioritizing other types of en-
gagements for the sake of sustainability, leaving the general population on a secondary
role for biobanks and leaving their engagement to third actors. Therefore, rather than
conceptualizing an “ideal type of population”, Spanish biobanks seem to conceptualize
them by default. Their absence, influenced by the circumstances, is what defines them
mostly as providers of biological samples rather than as social actors and, therefore,
stakeholders of the biobanking scene.
Compliance and Consensus in Finland
In Finland, which is a relative smaller country than Canada and Spain, the construction
of the public has been the result of a strong medical profession that has drawn on the
authority of the welfare state. Finland has been conducting research into national
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health risk factors since the 1950s and collecting DNA-samples for such purposes since
the beginning of 1980s (Aromaa et al. 2002, 7). According to a study funded by the
Finnish National Technology Agency Tekes, Finland has over 190 000 samples within
ten of its most significant epidemiological cohort studies (Technomedicum 2004). This
represents about 3.6 % of the country’s population, which in comparison to the UK Bio-
bank’s 500 000 samples from a population of over 60 million represents only under 1 %
sample of the population. According to the report, these samples and the related health
information could be used far more efficiently in the study of the human genome, dis-
eases, as well in the development of pharmaceuticals and treatment. The report also
sees genome research as uniting science and industry in a way that will give Finland an
edge over similar competing projects elsewhere in the world. In addition to the epi-
demiological cohort collections, Finland has pathology collections that amount to well
over 2 million samples.
Whereas the authority of the medical profession has been under attack in some
countries and contexts (Hess 2004; Brown and Zavestoski 2004), the Finnish medical
profession has always maintained a very strong presence in the way policy has been
developed in the country (cf. Tupasela 2007). In part, this trajectory is similar to many
of the other Nordic countries where the welfare state has played an important role in
improving the quality of people’s lives. Unlike Iceland, however, where the setting up
of deCode and the national legislation that would subsequently support it, there has
not been any major controversies in Finland regarding biomedical policy. In part this
can be explained by the lack of a larger national biobank project, but also in part by
the strong medical profession which has traditionally sought to construct a very willing
and eager population. Like some other countries, Finnish biomedical research has
drawn on rhetoric of common historic and thus genetic ancestry whereby Finnish
genes are seen to form an important part of developing drugs and treatments for Finns
(Tupasela 2015).
In many of the policy documents that we examined the population was con-
structed in a very positive and compliant way. In a 2003 policy document, for
example the general attitudes of various stakeholders were described in the follow-
ing way.
Compared to many other countries or regions, one of the Nordic countries’ greatest
strengths is its extremely wide-ranging and high-quality population-based registers,
and patient and sample databases, whose compilation has been extremely well-
received by decision-makers, researchers and the general population. (Academy of
Finland 2003, 16)
Although the Nordic countries, in general, have always sought to draw attention to
the excellence of their medical records and registers, Finland has also sought to inte-
grate the discussions related to use and management of tissue collections in relation to
their role in the national innovation system. In this sense, the public is ascribed a will-
ing and positive attitude in relation to the commercial opportunities that relate to bio-
banking. Like other Nordic countries Finland has also conducted a number of studies
into public perceptions of biobanking and tissue use (Tupasela and Snell 2012;
Hemminki et al. 2009; Sihvo et al. 2007). In many ways, these studies have bolstered
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the notion of a unified perception of biobankers despite the fact that there are differ-
ences in public opinion towards the biomedical use of tissue collections.
In a number of our interviews, with both policy makers and researchers, it was noted
that the use of tissue collections was seen as a potential source for commercial oppor-
tunities. As one publication related to biobanking noted.
As a counter question one can ask whether it is justified from the perspective of
Finnish taxpayers not to exploit the enormous commercial potential which Finnish
biomedical research has produced during the past years? (Käpyaho et al. 2004, 10)
This type of argument format was quite usual in the Finnish documents where, the
various ethical and legal issues were discussed on their merits and relevance in relation to
public expenditure, as well as commercial potential (cf. Tupasela 2008). Much like the
Spanish biobanks, engagement with the public was not seen as the primary task within
biobanking activities, but unlike Spain, however, Finnish policy makers and researchers did
not appear to need to distance themselves from the public to such a great degree. Instead,
in many of the documents we looked at, as well as in the interviews, the tone was very
direct in relation to presenting the function of public funding in relation to biobanks.
Research sample collections collected with public funding, diagnostic sample
collections and related information can be seen as being a part of the infrastructure
that supports research and innovations, whose efficient utilization can be seen to
benefit the whole society. […] In biobanking research, the interests of the researcher,
the research participant and society are parallel. Biobank research produces
significant new research findings. The translation of these findings into products and
services that contribute to public health requires also partnerships with the private
sector. Finland’s prosperity is based on the generation of innovations, their up-take
and the creation of new businesses. (Sosiaali- ja terveysministeriö 2007, 13)
The last couple of years have, however, created a new situation for biobank research
in Finland. A new Biobank Act (Act 688/2012) came to force in September 2013. The
act is one of its kind in Europe as it regulates directly and only biobanks of all types–
from population to clinical and disease based biobanks and public as well as private
biobanks. The Biobank Act defines criteria for biobanking and its passing has resulted
in a situation where all research infrastructures that called themselves biobanks prior
to the enactment of the Biobank Act have to apply for permit to function as a biobank
as defined by the act. This has created lots of activities in the field and most old tissue
collections will be or have already started the process of transferring to biobanks.
The two first biobanks–as defined in the act–got their permissions to start operation
in early 2014 from the National Supervisory Authority for Health and Welfare that
supervises biobanks. The two new biobanks are Auria Biobank (a clinical biobank in
the Turku hospital district) and THL Biobank (a national population-based biobank,
to which it transfers its major longitudinal cohorts). Auria Biobank’s goal is to get new
samples from every patient enrolled in the hospital. During the retrieval of a diagnostic
sample a surplus sample will be given to the biobank after receiving consent from the
patient. In addition, it is transferring old sample collections of the hospitals, as well as
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research project samples to the biobank. Unlike Iceland or the UK where the setting
up of large biobanks have spurred major public and professional debates, the Finnish
example has proven quite the contrary where there has been very little or no public
discussion related to the transfer of diagnostic samples or legacy collections into the
new biobanking framework. One could compare the move akin to taking all the sam-
ples in the London area and transferring them to UK Biobank, for example, without
any public debate over the move. According to the Auria Biobank website.
In biobank research the interests of the researchers, the research subject and society
are parallel. Finnish welfare is based on the development of innovations, their
uptake, as well as the development of new businesses (Auria Biobank 2014)
The idea that in biobank research the various stakeholders hold the same values and
goals is somewhat problematic, especially given the large amount of evidence from around
the world regarding differing perspectives, yet the statement is emblematic of the ways in
which biobankers in Finland tend to view their role in society, as well as their relationship
with various stakeholders, especially research subjects and the public, in particular.
This lack of public debate reflects the nature of the public engagement and the power
of the medical community in constructing policy. It also reflects the ways in which the
public have been constructed in a compliant and supportive manner, whereby policy
discussions are from the outset framed in a way that is difficult to problematize.
Discussion
In our research of biobank engagement strategies in six countries we have made a note
of the different ways in which various biobanks, as well as biobanking policies, have
sought to construct or bio-objectify the populations from which they source their
samples. We have observed that in much the same way that the people from whom the
samples are sourced help to form the identity and scope of the biobank itself, so does
the biobank and the policies and governance environment in which they operate help
to construct the population itself. We see these processes of bio-objectification as
attempts at stabilizing the populations from which they derive both their samples and
legitimacy from. We also see this iterative process between historical, political and
scientific narratives to be highly dynamic and contextualized, giving rise to different
types and forms of bio-objectification, which are generated though varying styles and
forms of engagement strategies.
The three countries from which we draw our examples – Canada, Spain and Finland –
are very different in terms of the historical and political trajectories in which their bio-
banking activities have operated. The Canadian federalist system has emphasized the
regional character of biobanking drawing on the specificities of each regions population
to highlight the significance that biobanking has for each regions population. As the vari-
ous biobanks have sought to construct a very positive picture of the various populations,
it is only very recently, however, that these policies have come under challenge as regional
biobanks are integrated into federal and international networks and people are expecting
to get more personal results back from the research system.
In Spain, recent political and economic challenges have prompted a very different ap-
proach to engagement and thus contributed to the construction of a very different type
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of public, which is far more distant and passive in relation to biobanking activities. Bio-
banks have often explicitly sought to keep the public at a distance and instead preferred
to develop stronger links with other actors, such as physicians and hospitals who act as
buffers for engaging with the public, as well as the people from whom samples are col-
lected. Although public engagement is described as useful and necessary, it is far from
being a top priority for Spanish biobanks and, given the scarce resources biobanks
count on, it seems like direct engagement strategies will not be carried out soon.
In Finland, the construction of a positive and willing population, whose interests are
parallel to those of researchers and society reflects a strongly medically driven and con-
trolled image of public perceptions. Much like in Spain, where there has been very little
public discussions surrounding biobanking policies, the Finnish strategy has sought to
develop a very expert led agenda concerning public interests. Finland and Spain differ,
however, in the sense that Spain has not undertaken many efforts to gage public percep-
tions through surveys, for example, while Canada and Finland are more similar in this
sense. As a result, recent Canadian and Finnish policy discourse tends to draw on its legit-
imacy from such studies, which would also suggest that biobanking efforts also draw on
other sources through which the public is constructed, such as in the case of Spain.
Bio-objectification has been seen as a way of stabilizing conceptions of patients within
medical research (Douglas 2012). Our study suggests that the forms of stabilization of
populations in relation to engagement practices are regionally and locally contingent,
whereby historical, political and scientific specificities can give rise to different ways in
which populations are constructed and engagement conceptualized. Igo’s notion of a mass
society constructed through surveys and questionnaires is informative in many ways with
regard to the construction of populations from which biobanks draw from, yet limited, in
that not all countries, regions or institutions seek to draw on surveys for further legitim-
acy. Instead, biobanks draw on a diverse range of material from which they seek to draw
legitimacy from. What is significant about these processes, however, is that they seem to
be very static. This creates a number of problems including an inability to quickly react
and adapt to changes in public perceptions, as well as the creation of particular types of
worldviews within specific contexts.
We believe that our cases show that the construction of populations through the
collection of biological samples does not only take place through the collection and
research process, but also through the interaction with such populations. This means
that biobanks, besides defining populations by analyzing the biological characteristics
of a population or by collecting population data, also describe those populations
through the way they interact with them. Similarly, the development of biobanks
draws heavily on the historical and political context in which they have developed.
Bio-objectification cannot, therefore, be seen as a unidirectional process where
science acts upon populations, but rather an iterative process where identity and
legitimacy are co-constructed. The local nature of the bio-objectification process may
pose a problem in relation to attempts to standardize and stabilized ethical, legal and
social practices surrounding biobanks internationally. Such attempts may not take
into account sufficiently regional differences and context, but rather suppose a
one-size-fits-all solution.
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